$NNVC

$1.25▲ -3.8% YTD

7 SEC 13D/G filings tracked · Last updated Oct 13, 2026

Filing History

News

NNVC ▼ -3.8% - NanoViricides, Inc.

CP $1.25▲ -3.8%Oct 13, 2026 · ThinkSabio Blog

$NNVC - Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides…

News

NNVC ▲ +1.4% - NanoViricides, Inc.

CP $1.48▲ +1.4%Oct 6, 2026 · ThinkSabio Blog

$NNVC - NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026…

News

NNVC ▼ -0.8% - NanoViricides, Inc.

CP $1.28▲ -0.8%Oct 5, 2026 · ThinkSabio Blog

$NNVC - NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Conti…

News

NNVC ▲ +4.0% - NanoViricides, Inc.

CP $1.56▲ +4.0%Sep 29, 2026 · ThinkSabio Blog

$NNVC - NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials…

News

NNVC ▼ -2.1% - NanoViricides, Inc.

CP $1.41▲ -2.1%Sep 28, 2026 · ThinkSabio Blog

$NNVC - Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Sa…

News

NNVC ▲ +5.2% - NanoViricides, Inc.

CP $1.61▲ +5.2%Sep 23, 2026 · ThinkSabio Blog

$NNVC - Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides…

News

NNVC ▼ -0.9% - NanoViricides, Inc.

CP $1.11▲ -0.9%Sep 8, 2026 · ThinkSabio Blog

$NNVC - Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Eb…